| Name | Title | Contact Details |
|---|---|---|
Geoff Belair |
Chief Technology Officer | Profile |
Hilsinger Company L.P. dba Hilco USA is a Plainville, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The b.well connected health platform provides an all-in-one integrated solution for consumer engagement, holistic health management, and cost containment. Our use of longitudinal aggregated data creates a complete picture of health for each consumer and is aggregated to allow for true population health management. Our unique approach to partner integration allows our customers to change their programs in real time as the health needs of their population change, not on an annual sales cycle. With the b.well platform there is one contract, one implementation and the elimination of point-solution fatigue. We provide real-time transparent dashboards to all customers highlighting return on investment, cost containment opportunities, engagement metrics and outreach campaign outcomes, clinical risk factors and disease states. b.well supports health plans, health systems, employers and pharmaceutical companies to bring their digital strategy to life and enables them to provide their employees, members and patients with the one thing they do not have today; one place to manage all aspects of their health.
Paradigm Health Plans is the industry leader in creating self-funded value-based benefit designs for a total solution for your workforce. Founded in 2007, Paradigm has been partnering with businesses nationally to empower employers and their workforce to actively manage their healthcare costs.
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.
Healthcare organizations and technology vendors connect to Redox once, then authorize what data they send to and receive from partners through a centralized hub. Redox`s cloud-based platform is vendor and standards agnostic and enables the secure and efficient exchange of healthcare data. This approach eradicates the need for point-to-point integrations and accelerates the discovery, adoption, and distribution of patient and provider-facing technology solutions. With hundreds of healthcare organizations and technology vendors exchanging data today, Redox represents the largest interoperable network in healthcare.